Tenofovir-associated Proteinuria
Overview
Affiliations
Proteinuria was observed in 27% of 153 patients taking tenofovir for more than 1 year. Concomitant protease inhibitor therapy and cumulative tenofovir exposure were independently associated with proteinuria in this cohort. Proteinuria was reversible in 11 of 12 patients who ceased tenofovir because of proteinuria without altering other medications. Clinicians should be aware that tenofovir can cause reversible proteinuria in patients with HIV.
Mugusi S, Shayo G, Sasi P, Fundikira L, Aris E, Sudfeld C South Afr J HIV Med. 2025; 26(1):1640.
PMID: 39967751 PMC: 11830870. DOI: 10.4102/sajhivmed.v26i1.1640.
Drug-Related Glomerular Phenotypes: A Global Pharmacovigilance Perspective.
Baptista A, Macedo A, Marreiros A, Coelho A, Perazella M J Clin Med. 2024; 13(16).
PMID: 39201010 PMC: 11355908. DOI: 10.3390/jcm13164869.
Chadwick D, Barker F, Smith C, Perditer O, Hardy Y, Owusu D BMC Nephrol. 2024; 25(1):241.
PMID: 39075393 PMC: 11288112. DOI: 10.1186/s12882-024-03537-7.
Peyriere H, Cournil A, Casanova M, Badiou S, Cristol J, Reynes J PLoS One. 2015; 10(11):e0142491.
PMID: 26571117 PMC: 4646508. DOI: 10.1371/journal.pone.0142491.
The role of drug transporters in the kidney: lessons from tenofovir.
Moss D, Neary M, Owen A Front Pharmacol. 2014; 5:248.
PMID: 25426075 PMC: 4227492. DOI: 10.3389/fphar.2014.00248.